Efficacy of switching from placebo to deucravacitinib treatment at Week 16 through Week 52 responses in patients who switched from placebo to deucravacitinib

Richard B Warren,1 April W Armstrong,1 Melinda Gooderham,1 Bruce Strober,2 Diamant Thaci,1 Shinichi Imakfuku,4 Howard Soven,1 Lynda Spelman,5 Neil J Korman,3 Min Zheng,6 Elizabeth Colston,7 John Throup,8 Sudeep Kundu,9

1Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester; 2Manchester NHMR Biomedical Research Centre, The University of Manchester, Manchester, UK; 3University of Southern California, Los Angeles, CA, USA; 4SKIRN Center for Dermatology, Queen’s University, and Probioty Medical Research, Peterborough, ON, Canada; 5Fahie University, New Haven, CT, and Central Connecticut Dermatology Research, Cromwell, CT, USA; 6University of Lübeck, Lübeck, Germany; 7Fukushima University Hospital, Fukushima, Japan; 8UGA School of Medicine, Los Angeles, CA, USA; 9Avery Clinical Research, Westollywood, QLD, Australia; 10Case Western Reserve University and University Hospitals, Cleveland, OH, USA;

2Second Affiliated Hospital, Zhejiang University School of Medicine, National Key Clinical Department of Dermatology, Hangzhou, Zhejiang Province, China; 3Bristol Myers Squibb, Princeton, NJ, USA; 4Oregan Medical Research Center, Portland, OR, USA

Objective

• To evaluate the efficacy of deucravacitinib over 52 weeks in POETYK PSO-1 and PSO-2.

Methods

Key design elements

• The POETYK PSO-1 and PSO-2 study designs are shown in Figure 2.

• Key eligibility criteria:

  • ≥18 years of age
  • Moderate-to-severe plaque psoriasis (Psoriasis Area and Severity Index [PASI] ≥10) for at least 3 months
  • Baseline psoriasis disease activity (PASI) and static Physician’s Global Assessment (sPGA) scores of 0 or 1 among patients with PASI 90 and sPGA 0/1 responses (secondary efficacy endpoints) were also maintained through Week 12 in patients who received continuous deucravacitinib treatment from Week 1 to Week 12 (Table 2).

Results

Baseline patient demographics and disease characteristics

• Patients who switched from placebo to deucravacitinib at Week 16 demonstrated PASI 75 and sPGA 0/1 responses (primary efficacy endpoint) and were well tolerated in patients with moderate to severe plaque psoriasis.

Table 1. Baseline patient demographics and disease characteristics

<table>
<thead>
<tr>
<th>Outcome measures</th>
<th>POETYK PSO-1</th>
<th>POETYK PSO-2</th>
</tr>
</thead>
<tbody>
<tr>
<td>PASI 75</td>
<td>57 (34.3)</td>
<td>59 (35.1)</td>
</tr>
<tr>
<td>sPGA 0/1</td>
<td>57 (34.3)</td>
<td>59 (35.1)</td>
</tr>
</tbody>
</table>

Table 2. Disposition of patients over 52 weeks

<table>
<thead>
<tr>
<th>Treatment arm</th>
<th>Patients (n)</th>
<th>Percentage (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Placebo</td>
<td>166</td>
<td>100 (99.1-100.0)</td>
</tr>
<tr>
<td>Deucravacitinib</td>
<td>332</td>
<td>100 (99.1-100.0)</td>
</tr>
</tbody>
</table>

Figure 3. Study designs

Figure 4. POETYK PSO-1: PASI 75 and sPGA 0/1 responses through Week 52 in patients who received continuous deucravacitinib treatment from Week 1 to Week 12 (Table 2).

Figure 5. POETYK PSO-1: percentage change from baseline in PASI through Week 52 in patients randomized to deucravacitinib and placebo (NRI)

Figure 6. POETYK PSO-2: PASI 75 and sPGA 0/1 responses through Week 52 in patients randomized to deucravacitinib and placebo (NRI)

Figure 7. POETYK PSO-2: DLQI 0/1 response through Week 52 in patients randomized to deucravacitinib and placebo (NRI)

Conclusions

• The phase 3 POETYK PSO-1 and PSO-2 trials demonstrated efficacy through Week 52 in patients with moderate to severe plaque psoriasis.

References


Acknowledgments

Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester NHMR Biomedical Research Centre, The University of Manchester, Manchester, UK; University of Southern California, Los Angeles, CA, USA; SKIRN Center for Dermatology, Queen’s University, and Probioty Medical Research, Peterborough, ON, Canada; Fahie University, New Haven, CT, and Central Connecticut Dermatology Research, Cromwell, CT, USA; University of Lübeck, Lübeck, Germany; Fukushima University Hospital, Fukushima, Japan; UGA School of Medicine, Los Angeles, CA, USA; Avery Clinical Research, Westollywood, QLD, Australia; Case Western Reserve University and University Hospitals, Cleveland, OH, USA; Second Affiliated Hospital, Zhejiang University School of Medicine, National Key Clinical Department of Dermatology, Hangzhou, Zhejiang Province, China; Bristol Myers Squibb, Princeton, NJ, USA; Oregan Medical Research Center, Portland, OR, USA

Disclosures

• Richard B Warren received grant support from AbbVie, AstraZeneca, BMS, Celgene, Gilead, Janssen, Kyowa Hakko Kirin, Leo Pharma, Merck, Novartis, Pfizer, Regeneron, Sanofi Genzyme, Sun Pharma, UCB, and Valeant; grants and personal fees from AbbVie, AstraZeneca, BMS, Celgene, Gilead, Janssen, Kyowa Hakko Kirin, Leo Pharma, Merck, Novartis, Pfizer, Regeneron, Sanofi Genzyme, Sun Pharma, UCB, and Valeant; and consulting fees from AbbVie, AstraZeneca, BMS, Celgene, Gilead, Janssen, Kyowa Hakko Kirin, Leo Pharma, and Merck.

• April W Armstrong received grants and personal fees from AbbVie, AstraZeneca, BMS, Celgene, Gilead, Janssen, Kyowa Hakko Kirin, Leo Pharma, Merck, Novartis, Pfizer, Regeneron, Sanofi Genzyme, Sun Pharma, UCB, and Valeant; and consulting fees from AbbVie, AstraZeneca, BMS, Celgene, Gilead, Janssen, Kyowa Hakko Kirin, Leo Pharma, and Merck.

• Melinda Gooderham received grants and personal fees from AbbVie, AstraZeneca, BMS, Celgene, Gilead, Janssen, Kyowa Hakko Kirin, Leo Pharma, Merck, Novartis, Pfizer, Regeneron, Sanofi Genzyme, Sun Pharma, UCB, and Valeant; and consulting fees from AbbVie, AstraZeneca, BMS, Celgene, Gilead, Janssen, Kyowa Hakko Kirin, Leo Pharma, and Merck.

• Bruce Strober received grants and personal fees from AbbVie, AstraZeneca, BMS, Celgene, Gilead, Janssen, Kyowa Hakko Kirin, Leo Pharma, Merck, Novartis, Pfizer, Regeneron, Sanofi Genzyme, Sun Pharma, UCB, and Valeant; and consulting fees from AbbVie, AstraZeneca, BMS, Celgene, Gilead, Janssen, Kyowa Hakko Kirin, Leo Pharma, and Merck.

• Diamant Thaci received grants and personal fees from AbbVie, AstraZeneca, BMS, Celgene, Gilead, Janssen, Kyowa Hakko Kirin, Leo Pharma, Merck, Novartis, Pfizer, Regeneron, Sanofi Genzyme, Sun Pharma, UCB, and Valeant; and consulting fees from AbbVie, AstraZeneca, BMS, Celgene, Gilead, Janssen, Kyowa Hakko Kirin, Leo Pharma, and Merck.

• Shinichi Imakfuku received grants and personal fees from AbbVie, AstraZeneca, BMS, Celgene, Gilead, Janssen, Kyowa Hakko Kirin, Leo Pharma, Merck, Novartis, Pfizer, Regeneron, Sanofi Genzyme, Sun Pharma, UCB, and Valeant; and consulting fees from AbbVie, AstraZeneca, BMS, Celgene, Gilead, Janssen, Kyowa Hakko Kirin, Leo Pharma, and Merck.

• Howard Soven received grants and personal fees from AbbVie, AstraZeneca, BMS, Celgene, Gilead, Janssen, Kyowa Hakko Kirin, Leo Pharma, and Merck.

• Lynda Spelman received grants and personal fees from AbbVie, AstraZeneca, BMS, Celgene, Gilead, Janssen, Kyowa Hakko Kirin, Leo Pharma, Merck, Novartis, Pfizer, Regeneron, Sanofi Genzyme, Sun Pharma, and UCB; and consulting fees from AbbVie, AstraZeneca, BMS, Celgene, Gilead, Janssen, Kyowa Hakko Kirin, Leo Pharma, and Merck.

• Neil J Korman received grants and personal fees from AbbVie, AstraZeneca, BMS, Celgene, Gilead, Janssen, Kyowa Hakko Kirin, Leo Pharma, Merck, Novartis, Pfizer, Regeneron, Sanofi Genzyme, Sun Pharma, UCB, and Valeant; and consulting fees from AbbVie, AstraZeneca, BMS, Celgene, Gilead, Janssen, Kyowa Hakko Kirin, Leo Pharma, and Merck.

• Min Zheng received grants and personal fees from AbbVie, AstraZeneca, BMS, Celgene, Gilead, Janssen, Kyowa Hakko Kirin, Leo Pharma, Merck, Novartis, Pfizer, Regeneron, Sanofi Genzyme, Sun Pharma, UCB, and Valeant; and consulting fees from AbbVie, AstraZeneca, BMS, Celgene, Gilead, Janssen, Kyowa Hakko Kirin, Leo Pharma, and Merck.

• Elizabeth Colston received grants and personal fees from AbbVie, AstraZeneca, BMS, Celgene, Gilead, Janssen, Kyowa Hakko Kirin, Leo Pharma, Merck, Novartis, Pfizer, Regeneron, Sanofi Genzyme, Sun Pharma, UCB, and Valeant; and consulting fees from AbbVie, AstraZeneca, BMS, Celgene, Gilead, Janssen, Kyowa Hakko Kirin, Leo Pharma, and Merck.

• John Throup received grants and personal fees from AbbVie, AstraZeneca, BMS, Celgene, Gilead, Janssen, Kyowa Hakko Kirin, Leo Pharma, Merck, Novartis, Pfizer, Regeneron, Sanofi Genzyme, Sun Pharma, UCB, and Valeant; and consulting fees from AbbVie, AstraZeneca, BMS, Celgene, Gilead, Janssen, Kyowa Hakko Kirin, Leo Pharma, and Merck.

• Sudeep Kundu received grants and personal fees from AbbVie, AstraZeneca, BMS, Celgene, Gilead, Janssen, Kyowa Hakko Kirin, Leo Pharma, Merck, Novartis, Pfizer, Regeneron, Sanofi Genzyme, Sun Pharma, and UCB; and consulting fees from AbbVie, AstraZeneca, BMS, Celgene, Gilead, Janssen, Kyowa Hakko Kirin, Leo Pharma, and Merck.

Presented at the 2021 Winter Clinical Dermatology Conference – Honolulu (HI); January 14-19, 2021; Kauai, HI, and Virtual

Email for Richard B Warren, MD: richard Warren@manchester.ac.uk

This poster may not be reproduced without written permission from the author.